Search

everythinglearnresearchcommunity

for

Search:↓

Innate lymphoid cells type 1 may contribute to alopecia areata by damaging hair follicles.

ILC1-like cells can cause alopecia areata by attacking hair follicles.

ILC1-like cells can independently cause alopecia areata by affecting hair follicles.

iNKT cells can help prevent and treat alopecia areata by promoting hair regrowth.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

Targeting immune tolerance issues in Alopecia Areata could restore hair growth and maintain remission.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.

6.1% of patients seeking PRP for hair loss had undiagnosed cicatricial alopecia, which PRP cannot treat.

An AI photographic device effectively tracked hair growth improvements in women treated for hair loss.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

No cure exists for alopecia areata, and treatments are personalized.

Hair regrowth was seen in 83% of children with alopecia, immune system plays a role in the condition, and various treatments showed effectiveness for hair and nail disorders.

Topical drugs and near-infrared light therapy show potential for treating alopecia.

The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.

The health of the gut may be important in developing new ways to prevent, diagnose, and treat alopecia areata.

Herbal lotions are effective for severe hair loss, with a 64.8% success rate, but relapse is common and long-term management requires allergen control and possible corticosteroid use.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.

The study suggests that a specific type of immune cell, memory-like NK cells, may increase during active hair loss in Alopecia areata.

Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.

Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

ILC1 cells contribute to hair loss in alopecia areata.

The document concludes that alopecia has significant social and psychological effects, leading to a market for hair loss treatments.